

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Please replace the title on page 47, line 1, starting with Table 6: Summary of activity of certain preferred
 138 analogs derived from the IL-6R (SEQ IDs NO:77 to NO:82)."


So as not to overburden the Patent Office Examiner, and following the recommendation of the Patent Office Sequence Help Desk, identical sequences with only an "L-D" form variation were represented only once in the enclosed Sequence Listing.

IN THE CLAIMS:

Please cancel claims 12-28.

Please add the following new claims:

29. (New) The backbone cyclized analog of claim 1 having the general formula:



wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R1 is (D)Bip, Gln, Lys, Lys(ZCL) Dab or absent;

R2 is (L) or (D)Lys, Gly, Ala, (D)Phe or Trp;

R3 is (D) Cit, Lys, (D)Bip or absent;

R4 is Orn, 4PyrAla, (L) or (D)Dab, (L) or (D)Arg, Lys or Dpr;


R5 is HomArg, Orn, Lys, Lys(ZCL), Arg, Arg(Mtr) or (D)Glu;

R6 is Asn, (L) or (D)Trp, (D)Gln or (D)Ala;

R7 is Arg, (L) or (D)Trp, (L) or (D)Gln, Abu, Glu or (p-NO2)Phe; and

Y2 is amide, thioether, thioester or disulfide.

30. (New) The backbone cyclized analog of claim 29 having the general formula 3:



Formula No. 3

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R¹ is (D)Bip, Gln, Lys, Lys(ZCL) or Dab;

R² is (D)Lys, Gly, Ala or Trp

R³ is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg, Lys or Dpr;


R⁴ is Lys, Lys(ZCL), Arg, Arg(Mtr) or (D)Glu;

R⁵ is Asn, Trp or (D)Ala;

R⁶ is Arg, (p-NO₂)Phe, (L) or (D)Trp, Gln, Abu or Glu; and

Y² is amide, thioether, thioester or disulfide.

31. (New) The backbone cyclized analog of claim 29 having the general formula 4:



Formula No. 4

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R¹ is (D)Phe or Lys;

R² is (D)Cit, Lys or (D)Bip;

R³ is Dpr, 4PyrAla or (L) or (D)Arg;

R⁴ is HomArg, Orn or Lys;


R⁵ is (D)Gln or (L) or (D)Trp;

R⁶ is (L) or (D)Gln or (p-NO₂)Phe; and

Y^2 is amide, thioether, thioester or disulfide.

32. (New) A pharmaceutical composition comprising a backbone cyclized IL-6 antagonist comprising a peptide sequence of five to twenty amino acids that incorporates at least one building unit, said building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester or disulfide, wherein the at least one building unit is connected via the bridging group to form a cyclic structure, together with a pharmaceutically acceptable carrier or diluent.

33. (New) The pharmaceutical composition of claim 14 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 1:



Formula No. 1

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R^{249} is Trp, (L) or (D)Lys, (L) or (D)Tyr or (D)Phe;

R^{250} is Arg;

R^{251} is (L) or (D)Leu or Lys;

R^{252} is (L) or (D)Arg;

R^{253} is (D) or (L)Phe;

R^{254} is Ala;

R^{255} is (D) or (L)Leu or is Lys;


R^{256} is absent or is (L) or (D)Arg;

R^{257} is (L) or (D)Tyr;

R^{258} is Ala; and


Y^2 is amide, thioether, thioester or disulfide.

34. (New) The pharmaceutical composition of claim 33 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula:




35. (New) The pharmaceutical composition of claim 33 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula: (D)Lys-Arg-(D)Leu-(D)Arg-(D)Phe-AlaC3-(D)Leu-Arg-(D)Tyr-AlaN3-NH₂

36. (New) The pharmaceutical composition of claim 33 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the formula:



B9
cont
37. (New) The pharmaceutical composition of claim 32 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula:



wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R1 is (D)Bip, Gln, Lys, Lys(ZCL) Dab or absent;

R2 is (L) or (D)Lys, Gly, Ala, (D)Phe or Trp;

R3 is (D) Cit, Lys, (D)Bip or absent;

R4 is Orn, 4PyrAla, (L) or (D)Dab, (L) or (D)Arg, Lys or Dpr;


R5 is HomArg, Orn, Lys, Lys(ZCL), Arg, Arg(Mtr) or (D)Glu;

R6 is Asn, (L) or (D)Trp, (D)Gln or (D)Ala;

R7 is Arg, (L) or (D)Trp, (L) or (D)Gln, Abu, Glu or (p-NO₂)Phe; and

Y2 is amide, thioether, thioester or disulfide.

38. (New) The pharmaceutical composition of claim 37 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 3:



Formula No. 3

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R¹ is (D)Bip, Gln, Lys, Lys(ZCL) or Dab;

R² is (D)Lys, Gly, Ala or Trp

R³ is Orn, 4PyrAla, (L) or (D)Dab, (D)Arg, Lys or Dpr;


R⁴ is Lys, Lys(ZCL), Arg, Arg(Mtr) or (D)Glu;

R⁵ is Asn, Trp or (D)Ala;

R⁶ is Arg, (p-NO₂)Phe, (L) or (D)Trp, Gln, Abu or Glu; and

Y² is amide, thioether, thioester or disulfide.

39. (New) The pharmaceutical composition of claim 37 wherein the IL-6 antagonist is a backbone cyclized peptide analog having the general formula 4:



Formula No. 4

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R¹ is (D)Phe or Lys;

R² is (D)Cit, Lys or (D)Bip;